These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 26279197)

  • 41. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
    Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A
    J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-transplantation lymphoproliferative disorders (PTLD) localized in the central nervous system: report from an international survey on PTLD.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):235-42. PubMed ID: 23538344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplant recipients.
    Cheng J; Moore CA; Iasella CJ; Glanville AR; Morrell MR; Smith RB; McDyer JF; Ensor CR
    Clin Transplant; 2018 May; 32(5):e13235. PubMed ID: 29517815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry.
    Aull MJ; Buell JF; Trofe J; First MR; Alloway RR; Hanaway MJ; Wagoner L; Gross TG; Beebe T; Woodle ES
    Transplantation; 2004 Dec; 78(11):1676-82. PubMed ID: 15591959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allograft involvement by lymphoproliferative disorders after lung transplantation: report from the PTLD. Int survey.
    Izadi M; Taheri S
    Prog Transplant; 2011 Dec; 21(4):353-9. PubMed ID: 22549000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update.
    Hertig A; Zuckermann A
    Transpl Immunol; 2015 Jun; 32(3):179-87. PubMed ID: 25936966
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.
    Yousem SA; Randhawa P; Locker J; Paradis IL; Dauber JA; Griffith BP; Nalesnik MA
    Hum Pathol; 1989 Apr; 20(4):361-9. PubMed ID: 2539321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents.
    Greenway SC; Butts R; Naftel DC; Pruitt E; Kirklin JK; Larsen I; Urschel S; Knecht K; Law Y
    J Heart Lung Transplant; 2016 Apr; 35(4):457-65. PubMed ID: 26746989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD.Int. Survey.
    Khedmat H; Taheri S
    Ann Transplant; 2010; 15(3):80-6. PubMed ID: 20877272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors.
    Dierickx D; Tousseyn T; Sagaert X; Fieuws S; Wlodarska I; Morscio J; Brepoels L; Kuypers D; Vanhaecke J; Nevens F; Verleden G; Van Damme-Lombaerts R; Renard M; Pirenne J; De Wolf-Peeters C; Verhoef G
    Leuk Lymphoma; 2013 Nov; 54(11):2433-40. PubMed ID: 23442063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
    Katz BZ; Pahl E; Crawford SE; Kostyk MC; Rodgers S; Seshadri R; Proytcheva M; Pophal S
    Pediatr Transplant; 2007 Feb; 11(1):58-65. PubMed ID: 17239124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009.
    Yoon SO; Yu E; Cho YM; Suh C; Kim KM; Han DJ; Lee SG; Huh J
    Clin Transplant; 2012; 26(1):67-73. PubMed ID: 21269330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Small intestinal involvement by lymphoproliferative disorders post-renal transplantation: a report from the post-transplant lymphoproliferative disorder international survey.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):487-94. PubMed ID: 23640619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.
    Francis A; Johnson DW; Craig J; Teixeira-Pinto A; Wong G
    Kidney Int; 2018 Oct; 94(4):809-817. PubMed ID: 30173897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-transplantation lymphoproliferative disorders in renal vs. simultaneous renal-pancreas allograft recipients: a survey and analysis of data from the literature.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 Jan; 24(1):1-7. PubMed ID: 23354184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong.
    Au WY; Lie AK; Kwong YL; Shek TW; Hawkins BR; Lai KN; Tang SC; Lo CM; Fan ST; Liu CL; Chan GC; Chau EM; Chiu SW; Liang R
    Leuk Lymphoma; 2002 Jul; 43(7):1403-7. PubMed ID: 12389620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.